BackReneo Pharmaceuticals Overview

Reneo Pharmaceuticals Other Liabilities

Latest other liabilities for RPHM: $0.

Get informed when a big investor buys or sells

+ Follow
Other Liabilities
$0.00

Peer average

Loading

Reneo Pharmaceuticals Other Liabilities History

Loading

Reneo Pharmaceuticals vs. peers: Other Liabilities Comparison

Loading

Reneo Pharmaceuticals Other Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Reneo Pharmaceuticals (RPHM) FAQ

Reneo Pharmaceuticals (RPHM) currently reports a other liabilities of $0 as of June 2026. In the prior-year period, the figure was $0. Use the charts on this page to explore Reneo Pharmaceuticals's other liabilities history and peer comparisons.

Reneo Pharmaceuticals's other liabilities changed from $0 to $0 (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Reneo Pharmaceuticals reported $0 in other liabilities as of June 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other liabilities of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Reneo Pharmaceuticals, and consider following RPHM for alerts when major investors trade the stock.

Reneo Pharmaceuticals is classified in the Healthcare sector. On other liabilities, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RPHM with unrelated industries.